Mechanism of Action - Jakavi
Uncontrolled JAK/STAT signalling is characteristic of both polycythaemia vera (PV) 1–5 a nd for myelofibrosis (MF). 6
JAKs are tyrosine kinases that transmit signals from cytokine or growth factor receptors to the cell...Twitter Linkedin Facebook Pinterest Google plusPatient Resources - Jakavi
Mechanism of Action - Kisqali
Ribociclib is a selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6, resulting in 50% inhibition (IC50) values of 0.01 (4.3 ng/ml) and 0.039 μM (16.9 ng/ml) in biochemical assays, respectively. These kinases are activated upon binding to D-...
Twitter Linkedin Facebook Pinterest Google plusPatient Resources - Scemblix
Practical information - Scemblix
ESH Berlin 2023 Highlights
Scientific Publications & Other Resources
Safety Profile - Jakavi
Below is a selection of the observed side effects; please refer to the SmPc or the package leaflet for the complete list.
Myelosuppression
Patients who develop anaemia may need blood transfusions. Dose adjustment or...Twitter Linkedin Facebook Pinterest Google plusDosing / Administration
Posology The recommended dose is 40 mg twice daily at approximately 12‑hour intervals. If a dose is missed by less than 6 hours, it should be taken and the next dose should be taken as scheduled. If a dose is missed by more than...Twitter Linkedin Facebook Pinterest Google plus
